Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Long-Term Debt Repayments (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Long-Term Debt Repayments for 16 consecutive years, with $1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed 0.0% to $1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.0 million, a 30.71% decrease, with the full-year FY2024 number at $6.0 million, up 47.23% from a year prior.
  • Long-Term Debt Repayments was $1.0 million for Q3 2025 at Harvard Bioscience, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $3.0 million in Q1 2024 to a low of $500000.0 in Q1 2021.
  • A 5-year average of $963157.9 and a median of $750000.0 in 2022 define the central range for Long-Term Debt Repayments.
  • Peak YoY movement for Long-Term Debt Repayments: crashed 98.93% in 2021, then skyrocketed 96.69% in 2023.
  • Harvard Bioscience's Long-Term Debt Repayments stood at $500000.0 in 2021, then skyrocketed by 50.0% to $750000.0 in 2022, then changed by 0.0% to $750000.0 in 2023, then skyrocketed by 33.33% to $1.0 million in 2024, then changed by 0.0% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Long-Term Debt Repayments are $1.0 million (Q3 2025), $1.0 million (Q2 2025), and $1.0 million (Q1 2025).